Cardiff Oncology, Inc. (CRDF)
NASDAQ: CRDF · Real-Time Price · USD
1.990
+0.110 (5.85%)
Mar 9, 2026, 4:00 PM EDT - Market closed
Cardiff Oncology Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Revenue | 0.59 | 0.68 | 0.49 | 0.39 | 0.36 | Upgrade
|
| Revenue Growth (YoY) | -13.18% | 39.96% | 26.42% | 7.52% | -1.91% | Upgrade
|
| Cost of Revenue | 2.38 | 1.66 | 32.86 | 27.11 | 17.38 | Upgrade
|
| Gross Profit | -1.78 | -0.98 | -32.37 | -26.72 | -17.02 | Upgrade
|
| Selling, General & Admin | 14.22 | 12.48 | 13.04 | 13.18 | 11.84 | Upgrade
|
| Research & Development | 32.95 | 35.19 | - | - | - | Upgrade
|
| Operating Expenses | 47.18 | 47.67 | 13.04 | 13.18 | 11.84 | Upgrade
|
| Operating Income | -48.96 | -48.65 | -45.41 | -39.9 | -28.86 | Upgrade
|
| Interest & Investment Income | 3.1 | 3.26 | 4.07 | 1.58 | 0.26 | Upgrade
|
| Other Non Operating Income (Expenses) | 0.01 | -0.04 | -0.1 | -0.38 | 0.3 | Upgrade
|
| EBT Excluding Unusual Items | -45.85 | -45.43 | -41.44 | -38.7 | -28.29 | Upgrade
|
| Pretax Income | -45.85 | -45.43 | -41.44 | -38.7 | -28.29 | Upgrade
|
| Net Income | -45.85 | -45.43 | -41.44 | -38.7 | -28.29 | Upgrade
|
| Preferred Dividends & Other Adjustments | 0.03 | 0.02 | 0.02 | 0.02 | 0.02 | Upgrade
|
| Net Income to Common | -45.88 | -45.46 | -41.47 | -38.73 | -28.32 | Upgrade
|
| Shares Outstanding (Basic) | 67 | 48 | 45 | 44 | 39 | Upgrade
|
| Shares Outstanding (Diluted) | 67 | 48 | 45 | 44 | 39 | Upgrade
|
| Shares Change (YoY) | 40.27% | 6.65% | 2.47% | 11.71% | 86.97% | Upgrade
|
| EPS (Basic) | -0.69 | -0.95 | -0.93 | -0.89 | -0.73 | Upgrade
|
| EPS (Diluted) | -0.69 | -0.95 | -0.93 | -0.89 | -0.73 | Upgrade
|
| Free Cash Flow | -37.97 | -37.77 | -31.47 | -34.83 | -23.25 | Upgrade
|
| Free Cash Flow Per Share | -0.57 | -0.79 | -0.70 | -0.80 | -0.60 | Upgrade
|
| Gross Margin | - | -143.04% | - | - | - | Upgrade
|
| Operating Margin | -8256.32% | -7123.13% | -9305.74% | -10337.31% | -8037.60% | Upgrade
|
| Profit Margin | -7736.26% | -6655.20% | -8496.93% | -10033.16% | -7887.19% | Upgrade
|
| Free Cash Flow Margin | -6402.53% | -5530.45% | -6448.57% | -9022.28% | -6474.93% | Upgrade
|
| EBITDA | -48.6 | -48.25 | -45.01 | -39.67 | -28.4 | Upgrade
|
| D&A For EBITDA | 0.36 | 0.4 | 0.4 | 0.24 | 0.45 | Upgrade
|
| EBIT | -48.96 | -48.65 | -45.41 | -39.9 | -28.86 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.